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Objective: Critical limb ischemia (CLI) is a peripheral arterial disease manifested by drastically diminished blood flow to
the legs, pain at rest, nonhealing wounds, and gangrene caused by atherosclerosis. Significant tissue necrosis is associated
with late stage CLI and the patients have a poor prognosis. Necrotic and apoptotic cells activate complement and bind
complement inhibitor C4b-binding protein (C4BP). The major isoform of C4BP is composed of seven identical -chains
and one -chain, here termed C4BP, whereas upon inflammation a normally less abundant isoform is upregulated that
is exclusively composed of -chains. Measuring the -chains of C4BP includes both isoforms and is termed total C4BP
(C4BPtot). The hypothesis of this study was that levels of complement activation and C4BP are predictive for the severity
of the disease and that their measurement might be of clinical advantage.
Methods: This was a prospective, single-center study of 259 consecutive patients with CLI admitted to a secondary referral
center for vascular diseases. Interventions included evaluation of soluble terminal complement complexes (C5b-9),
C4BPtot and C4BP, lipid levels, the inflammatory mediators tumor necrosis factor-, interleukin-6, 8-iso-prostaglandin
F2, high-sensitivity C-reactive protein, neopterin, plasma homocysteine, and plasma endothelin-1 in plasma as well as
resistance to activated protein C and ankle blood pressure. All data were compared with an age-matched population based
control group of 219 currently healthy individuals.
Results: The data are presented as mean  SEM/median. CLI patients showed systemic complement activation (1.17 
0.06/1.13 AU/mL vs 0.69 0.07/0.59 AU/mL in healthy controls, P< .0001), which was even higher in patients with
gangrene (1.33  0.11/1.28 AU/mL vs 1.1  0.08/1.0 AU/mL, P  .0264), who also showed increased C4BP levels
(421  28.6/386 g/mL vs 341  10.8/318 g/mL for C4BPtot, P  .0248; 374  25.4/332 g/mL vs 305 
9.5/285 g/mL for C4BP, P  .0581). C4BP plasma levels were significantly elevated in CLI patients in comparison
to healthy controls (351 8.1/322 g/mL vs 297 8.0/288 g/mL for C4BPtot, P .0001; 314 7.0/287 g/mL
vs 265  7.0/263 g/mL for C4BP, P  .0004) and correlated to levels of interleukin-6 (Ptot/  .0048/.0019),
high-sensitivity C-reactive protein (P < .0001), leukocyte (Ptot/  .0086/.0043) and platelet count (P  .0001),
LDL/HDL ratio (Ptot  .0151) and HDL (Ptot/  .0047/.0177), but not to tumor necrosis factor-.
Conclusions: Increased complement activation and C4BP plasma levels are related to the degree of tissue necrosis and
disease severity of critical limb ischemia. This knowledge in combination with the found correlations to other biomarkers
is useful for understanding the pathophysiology of the disease. ( J Vasc Surg 2009;50:100-6.)Critical limb ischemia (CLI) is characterized by chronic
ischemic rest pain, ulcers, or gangrene attributable to arte-
rial occlusive disease.1 The incidence is approximately 500
to 1000 per million a year in western countries, with the
highest rates among older subjects, smokers, and diabet-
ics.1,2 The 1-year mortality in CLI is around 20%,3 and the
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100rate of primary amputation ranges from 10% to 40%.Due to
the negative impact on quality of life and the poor progno-
sis, both in terms of limb salvage and survival, CLI is a
critical public health issue.2,4
The complement system is an essential part of the
innate immune system in front line of defense against
bacterial infections. It bridges innate and adaptive immu-
nity and is also important for the removal of immune
complexes and dying cells.5 Complement is tightly con-
trolled by several soluble or membrane bound complement
inhibitors, but erroneous or excessive activation contrib-
utes significantly to the pathology of many inflammatory
diseases. C4b-binding protein (C4BP) is the major soluble
inhibitor of the classical and lectin pathways of complement
and circulates in complex with the vitamin K-dependent
protein S, a cofactor to the coagulation inhibitor activated
protein C (APC), thereby linking complement with the
coagulation system.6 C4BP is a large plasma glycoprotein
of 500 kDa and mainly produced in the liver. The major
isoform of C4BP is composed of seven identical -chains
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C4BP).
7 The subunits are covalently linked by disulfide
bonds at the C terminus.8 C4BP is an acute phase reactant
because its plasma level increases during inflammation and
after trauma.9 However, upon trauma, there is mainly
upregulation of the normally less abundant isoform of
C4BP that is composed exclusively of -chains.10 By mea-
suring the -chains, all forms of C4BP are detected and
hence they are termed total C4BP (C4BPtot). Accordingly,
the expression of - and -chains has been shown to be
differentially regulated by cytokines.11 Recent investiga-
tions revealed that C4BP regulates complement also on
apoptotic and necrotic cells.12,13
Due to the fact that CLI is an inflammatory disease and
often associated with significant tissue necrosis, we hypoth-
esized that complement is activated and that levels of C4BP
are increased in CLI patients and correlate with the degree
of tissue damage and with other biomarkers of the disease.
Therefore, we have measured level of complement activa-
tion as well as C4BP plasma levels in CLI patients and
correlated these values with a number of inflammatory
markers.
METHODS
Participants. The Vascular Center at Malmö Univer-
sityHospital is the referral center for all patients with CLI in
southern Sweden. During a 14-month period, 316 consec-
utive patients were referred to the center with a confirmed
diagnosis of CLI, and 259 consented to participate in the
present study. The study protocol conformed to the Dec-
laration of Helsinki, and all participants gave written in-
formed consent. The Lund University Regional Ethical
Review Board approved the study.
The diagnosis of CLI was made in accordance with
TransAtlantic Inter-Society Consensus scientific criteria1,4
of ulceration, gangrene, or rest pain caused by peripheral
arterial disease proven by ankle pressure (50 to 70 mm
Hg), reduced toe pressure (30 to 50mmHg), or reduced
transcutaneous oxygen tension (TCPO2). Diagnosis was
confirmed by an experienced vascular surgery consultant
and by toe pressure measurements in those patients where
the arteries in the affected leg were noncompressible, and
the ankle pressure was 50 to 70 mm Hg.1
A population based control group of currently healthy
individuals including 219 subjects of both sexes and with-
out symptomatic cardiovascular disease or peripheral arte-
rial atherosclerosis was also analyzed. These patients were a
part of a follow-up program for the Preventive Medicine
Project in Malmö.14
Patient variables. Gangrene was defined as visible
tissue loss on clinical examination. Body mass index was
calculated as weight in kilograms/height in m2. Serum
levels of triglycerides and total, low-density lipoprotein
(LDL), and high-density lipoprotein (HDL) cholesterol
were determined by a DAX 48 automatic analyzer (Bayer
AB, Gothenburg, Sweden). Plasma homocysteine, a risk
factor for cardiovascular diseases, was analyzed by a high-performance liquid chromatographic assay and resistance
to APC with a predilution of sample plasma in factor
V-deficient plasma. All methods were previously described
in detail.15
Blood sampling. EDTA-plasma was immediately pre-
pared after taking the blood samples, kept cold until stored
in a –70°C freezer within 1 hour.
Determination of terminal complement complex
(TCC) formation. Deposition of TCCs on the solid phase
was based on reaction with mAb aE11 specific for a neo-
epitope exposed when C9 is incorporated in the complex16
followed by biotin-conjugated mAb 9C4-RQ-B directed
against humanC617 andHRP-conjugated streptavidin (Dako
SwedenAB, Stockholm, Sweden)with1,2-phenylenediamine
dihydrochloride (OPD,Dako) as substrate using absorbance
values at 490 nm to represent the relative amount of bound
TCCs in the wells.
ELISA for determination of C4BP concentrations.
The plates were coated with 5 g/mL rabbit antibody
PK9008 (generated in house) overnight at 4°C in 75 mM
sodium carbonate. After quenching for 1 hour with 50mM
Tris-HCl, 0.15 M NaCl, 0.1% Tween, pH 7.5 (washing
buffer) supplemented with 3% fish gelatin, the plates were
washed four times and incubated for 1 hour with the
plasma. After another four washes, 5 g/mL of MK104
(for detection of C4BPtot) and MK2B (for detection of
C4BP) were added and incubated for 1 hour. Goat anti-
mouse antibody, conjugated with horseradish peroxidase
(Dako), was added after another four washes and incubated
for 1 hour. After the last four washes, the plates were
developed using OPD as substrate, and the absorbance at
490 nm was measured spectrophotometrically. The anti-
bodies were a kind gift of Prof. B. Dahlbäck (Lund Univer-
sity).
Analysis of inflammatory mediators. To determine
the inflammatory immune status of the patients, the follow-
ing acute phase reactants and inflammatory mediators were
analyzed: the proinflammatory cytokines plasma tumor ne-
crosis factor- (TNF-) and interleukin (IL)-6 were mea-
sured by ELISA using commercially available test kits
(Pharmingen, Stockholm, Sweden). Plasma neopterin, an-
other indicator for a proinflammatory immune status, was
determined by ELISA and the acute phase protein serum
high-sensitivity C-reactive protein (hs-CRP) by rate turbi-
dimetry. Wemeasured the vaso constricting peptide plasma
endothelin-1 (ET-1), a marker for arterial hypertension, by
radioimmunoassay and the prostaglandin-related inflam-
matory mediator plasma 8-iso-prostaglandin F2 by en-
zyme immunoassay. Detection limits as well as intra- and
inter-assay coefficients were previously described.15
Statistics. All variables were recorded in a database,
and statistical analyses and calculations were performed
using JMP 7 (SAS Institute AB, Solna, Sweden) and SPSS
(SPSS Sweden AB, Kista, Sweden). Statistical significance
was assessed using univariate analysis, whereby Spearman’s
rank correlation was performed for continuous variables
and Mann-Whitney U-test for binary variables. All tests
were nonparametric and two-tailed, and P  .05 was con-
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a multiple regression analysis was used. Log-transformations
of the outcome variables (C4BP or TCC) have been used to
decrease the influence of outliers and to obtain regression
residuals that are more symmetrically distributed. All variables
with P  .30 in the univariate analysis were entered in a
multiple regression model. One variable was then omitted
at a time, starting with the variable with the highest P value
and stopped when all remaining variables had P  .10.
Using this method, variables, which were highly significant
at the 5% level and revealed the strongest direct correlations
to the outcome variables, could have been determined. The
multiple regression P values are separately listed for the
corresponding variables. If not otherwise stated, the results
are presented as mean  standard error of mean/median
(25th-75th percentile).
RESULTS
CLI patients show systemic complement activation
and elevated C4BP plasma levels. Complement activa-
tion, defined by the presence of pathologic levels of circu-
lating TCCs (0.9 AU/mL), could be measured in the
patient cohort with the highest levels in those with gan-
grene (Fig 1, A). The controls showed no complement
activation. C4BP plasma levels were significantly higher in
CLI patients compared with age-matched healthy controls
(Fig 1, B). Further dividing the patient group, the ones
suffering from gangrene showed significantly higher C4BPtot
levels than those without (Fig 1, C). In accordance with
that, significantly elevated levels of C4BP were found in
patients who were considered for amputation (Table I).
Neither TCC nor C4BP levels were significantly increased
in patients with leg ulcers in comparison to patients without
ulcers.
Gender and age correlation of C4BP. In the healthy
control population, the concentration of C4BP was signif-
icantly higher in women than in men (310 g/mL vs 278
g/mL, P  .002 for C4BPtot; 274 g/mL vs 253 g/
mL, P  .01 for C4BP). However, no such difference
could be demonstrated in CLI patients. Neither in patients
nor in healthy controls, C4BP plasma levels correlated with
age. The participant’s demographic data are summarized in
Table II.
Correlation between C4BP and plasma levels of
inflammatory mediators. In patients, both C4BPtot and
C4BP were significantly correlated with IL-6 (Fig 2, A).
However, no significant correlation was found with TNF-
(Fig 2, B), although levels of this proinflammatory cytokine
were increased in patients (controls: 1.23  0.13/0.77
[0.55-1.22] pg/mL; patients: 2.21  0.22/1.55 (0.99-
2.53) pg/mL). The strongest correlation in patients was
found between C4BP and hs-CRP levels (Fig 2,C; multiple
regression P value: P  .0001). As shown before, hs-CRP
was significantly correlated with both proinflammatory cy-
tokines, IL-6 and TNF-.15 Furthermore, the level of
circulating TCCs was significantly correlated with IL-6
(P .0431, r .2425) and hs-CRP (P .0045, r .3483;
multiple regression P value: P  .027). Both forms ofC4BP correlated significantly with leukocyte count (Fig 2,
D), but not with 8-iso-prostaglandin F2 and neopterin.
Correlation between C4BP plasma levels and lipid
metabolism. In the patients, positive correlations were
observed between C4BP and triglyceride levels (Fig 3, A;
multiple regression P value: P  .001) as well as for C4BP
and LDL/HDL ratio (Fig 3, B). Consistently with that,
C4BP correlated negatively with HDL (Fig 3, C). No
Fig 1. Systemic complement activation and elevated C4BP
plasma levels in critical limb (CLI) ischemia patients. A shows
complement activation, determined by presence of circulating
terminal complement complexes (TCCs), in CLI patients (1.17
0.06/1.13 [0.73-1.45] AU/mL; n  70) in comparison to
healthy controls (0.69 0.07/0.59 [0.37-0.88] AU/m; n 47)
and in patients with (1.33 0.11/1.28 [1.07-1.70] AU/mL; n
24) and without gangrene (1.1 0.08/1.0 [0.72-1.37] AU/mL;
n  48). B illustrates increased plasma levels of C4BPtot and
C4BP in CLI patients (351  8.1/322 [255-412] g/mL for
C4BPtot; 314 7.0/287 [222-366]g/mL for C4BP; n 194)
compared with healthy controls (297  8.0/288 [247-329]
g/mL for C4BPtot; 265  7.0/263 [227-294] g/mL for
C4BP; n  196). C demonstrates C4BPtot and C4BP plasma
levels in CLI patients with (421  28.6/386 [296-469] g/mL
for C4BPtot; 374 25.4/332 [255-458] g/mL for C4BP; n
24) and without gangrene (341  10.8/318 [244-403] g/mL
for C4BPtot; 305  9.5/285 [220-363] g/mL for C4BP; n 
170). *Denotes significant P value, evaluated using Mann-
Whitney U-test, the horizontal line for each data set represents the
median.correlation was determined with cholesterol levels. In the
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levels (P tot .0002, rtot .2628; P  .0041, r  .2049)
and cholesterol (P tot  .0140, rtot  .1758), but not with
LDL/HDL ratio or HDL.
Correlations between C4BP plasma levels and other
patient variables. Patients with pathologic levels of TCCs
showed significantly increased platelet count (P  .0132,
r  .2949). Furthermore, the platelet count correlated
significantly with both forms of C4BP (Ptot .0001, rtot
.2714; P  .0001, r  .2693; multiple regression P
value: P  .015). Interestingly, the APC-resistant patients
(n  24) showed significantly increased levels of TCCs
(1.79  0.23/1.75 [1.41-2.35] AU/ml vs 1.09  0.08/
1.0 [0.62-1.37] AU/ml, multiple regression P value: P 
.007), but no change in C4BP levels. Only in patients,
C4BPtot significantly correlated with BMI (Ptot  .0361,
rtot .1525) and with patient weight (Ptot .0410, rtot
.1477). C4BP was not correlated with ET-1, homocys-
teine, hemoglobin, creatinine, or ankle pressure in the
patients.
C4BP plasma levels and pharmacologic therapy.
The C4BP plasma levels were significantly increased in
patients treated with antibiotics (Table I). Since the pa-
tients were treated with different kinds of antibiotics, the
elevated C4BP level might be due to a general influence of
these drugs on liver metabolism or it might be due to
infections and following acute phase reactions. Both
C4BPtot and C4BP levels were significantly lower in pa-
tients treated with the anticoagulant warfarin or inhibitors
of the renin-angiotensin system in comparison to patients
without such treatments (Table I). The correlation of
C4BP with the inhibitors of the renin-angiotensin system
Table I. C4BP plasma concentrations in different subgrou
C4BPtot [g/mL
Amputation (n  24) 418  28.6/377 (285
No amputation (n  170) 341  10.8/317 (247
Antibiotic-treated (n  47) 378  20.7/371 (267
Not antibiotic-treated (n  147) 342  11.7/316 (250
Warfarin-treated (n  24) 258  28.2/241 (213
Not warfarin-treated (n  170) 364  10.6/338 (265
ACE inhibitor-treated (n  67) 319  17.2/289 (230
Not ACE inhibitor-treated (n  127) 368  12.5/339 (268
Significance of differences was determined using Mann-Whitney U-test, dis
aSignificant P value.
bMultiple regression P value.
Table II. Demographic data of the participants (mean 
SEM/median [25th-75th percentile]; n)
CLI Patients Controls
Age (y) 75.1  0.64/76 (68-82) 67.9  0.11/67 (67-68)
Female/
Male 121/138 117/101was not significant anymore after the multiple regressionanalysis and therefore it most likely involves an indirect
effect. The following treatments did not affect the concen-
tration of C4BP in plasma: antiplatelet drugs, -blockers,
Fig 2. Correlation between C4BP and plasma levels of inflamma-
tory mediators. A illustrates the correlation of IL-6, B of TNF- and
C of hs-CRP plasma levels with C4BPtot and C4BP plasma levels
in CLI patients. D demonstrates the correlation between leukocyte
count and C4BPtot as well as C4BP plasma levels. *Denotes signifi-
cant P value, r Spearman’s rank correlation coefficient.
f patients with critical limb ischemia
P C4BP [g/mL] P
) .0430a 383  25.3/340 (258-499) .0240a
) 304  9.5/284 (221-361)
) .0411a 338  18.3/335 (241-414) .0496a
) 305  10.4/284 (221-354)
) .0001a 218  24.8/209 (178-250) .0001a
(.0001)b
) 327  9.3/308 (246-375)
) .0219a 285  15.2/263 (205-358) .0210a
(.084)b
) 329  11.1/303 (246-372)
are mean  SEM/medians (25th-75th percentile).ps o
]
-508
-403
-458
-394
-311
-423
-399
-419
playeddiuretics, calcium channel blockers, or lipid lowering drugs.
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on C4BP plasma levels. No significant differences in
C4BP plasma level could be detected between patients with
or without diabetes, previous stroke, angina pectoris, or
acute myocardial infarction. Furthermore, neither in pa-
tients nor in controls smoking influenced C4BP and C4BP
was not correlated with 1-year survival.
Summarizing the data, a multiple regression analysis
revealed that the C4BP levels are most strongly and directly
correlated to hs-CRP and triglyceride levels as well as to
platelet count and warfarin-treatment. The most important
determinants correlated to TCC levels are hs-CRP levels
and APC resistance. All correlations found with the univar-
iate regression method are equally statistically significant,
but they might reflect indirect influences of the parameters
via a third variable.
DISCUSSION
In this study, we demonstrated that patients suffering
from CLI showed on-going complement activation, as
determined by presence of pathologic levels of circulating
TCCs that are the final product of the complement cascade.
Furthermore, the plasma level of the complement inhibitor
C4BP was upregulated in these patients compared with
healthy controls. Both levels of plasma TCCs and C4BPtot
Fig 3. Correlation between C4BP and lipid plasma levels.
A illustrates the correlation of triglyceride levels, B the correlation
with LDL/HDL ratio and C the correlation of HDL levels with
C4BPtot and C4BP plasma levels in CLI patients. *Denotes
significant P value, r  Spearman’s rank correlation coefficient.were highest in patients with gangrene. CLI is an inflam-matory disease, which is caused by reduced blood flow to
the external limbs; this might lead to significant tissue
necrosis especially when gangrene arises. In this context,
complement can either be activated by CRP or directly by
necrotic and apoptotic cells. According to the multiple
regression analysis, CRP was correlated strongest with
C4BP and TCC, which indicates that it involves a direct
relationship, whereas the correlation to gangrene might be
indirect. However, the complement inhibitor C4BP ap-
pears to be upregulated by the organism when there is
significant tissue necrosis. It binds damaged cells and pre-
vents excessive inflammation evoked by these cells due to
the fact that they also bind large amounts of C1q, the
initiator of the classical complement pathway.12,18 There-
fore it should be beneficial to increase C4BP synthesis in
states with pronounced tissue destruction as this still allows
complement activation to the C3-level but prevents further
inflammatory events such as the generation of anaphylatox-
ins. It is unclear, however, which mediators are responsible
for this upregulation. Since there was no significant corre-
lation between levels of C4BP and TCCs, it seems that the
activation of complement itself does not initiate the up-
regulation of C4BP. Hence, the increase in C4BP might
arise as result of general acute phase reaction.
The measurement of systemic levels of TCC and C4BP
does not allow drawing conclusions about local effects in
the skin or muscles, and it does not differentiate between
increased consumption and decreased expression of the
proteins, but it is most likely that both TCC and C4BP
levels are much higher in necrotic tissue, since complement
activation is known to take place in such areas and since
C4BP is known to bind to dying cells. Plasma levels provide
information about the balance between newly synthesized
and consumed protein. It would also be interesting to
measure the local concentrations of C4BP and TCC in
specific organs of CLI patients. We plan to investigate this
issue in the future.
A significant increase in C4BP was observed in patients
who were considered for amputation. Due to atherosclero-
sis, insufficient oxygen supply often leads to tissue necrosis
in the limbs. If there is no chance for tissue rescue, ampu-
tation is often the last possibility to protect the healthy limb
parts. Since binding of C4BP to dying cells is important to
prevent inflammation, it is reasonable that we found in-
creased C4BP levels in these patients. In summary, TCC
and C4BP plasma levels are related to the degree of tissue
necrosis in CLI and their determination can give informa-
tion about the disease extent.
C4BP is an acute phase protein and increases in con-
centration upon infection and inflammation.19 Acute phase
proteins are upregulated by IL-6, IL-1, and TNF-, and
these three cytokines have been suggested to increase syn-
thesis of C4BP in vitro. We found that both C4BPtot and
C4BP are significantly correlated with IL-6 in vivo, which
is consistent with earlier in vitro findings.9 However,
no significant correlation was found between C4BP and
TNF-, although levels of this proinflammatory cytokine
were increased in the patients. This demonstrates that
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least in CLI. These results are in agreement with studies of
C4BP secretion from HepG2 cells, where it was observed
that IL-6 upregulates C4BP secretion more significantly
than IL-1 and TNF-.9,20 Furthermore, TNF- did not
upregulate C4BP in Hep3B and counteracted effects of
IL-6.11 A relation between complement activation and
IL-6 has been documented before. On the one hand, C5a
induces an increase in IL-621 but IL-6 also plays a role in
upregulation of the C5a receptor.22
The strongest correlation from the multiple regression
analysis was obtained between C4BP levels and hs-CRP a
major acute phase protein. A highly significant correlation
between total C4BP (not distinguishing C4BP forms) and
CRP with r  .345 has been previously reported,19 while
we found a correlation coefficient of r .3642 for C4BPtot.
Another study reported an r value of .567.23 It is remark-
able that levels of C4BP and CRP are so closely correlated.
CRP binds C1 of the classical pathway, which leads to
activation of complement. We found increased amounts of
TCCs in patients with elevated CRP. This is in agreement
with data showing that CRP frequently colocalizes with
TCC in the intima of early atherosclerotic lesions of coro-
nary arteries.24 A certain level of complement activation is
usually beneficial, as targets opsonized with CRP and fol-
lowing complement factors will be taken up by phagocytes.
However, too much activation could lead to overt inflam-
mation and tissue damage. Therefore, in order to control
the level of complement activation, CRP interacts also with
complement inhibitors C4BP25 and factor H.26 Strikingly,
even though C4BP was only correlated with IL-6 and not
with TNF-, hs-CRP was, as expected, highly correlated
with both proinflammatory cytokines. This indicates a spe-
cific interaction between the C4BP and IL-6 regulating
pathways.
The positive correlations between both forms of C4BP
and leukocyte count in patients are in agreement with an
earlier study, showing that C4BP correlated with erythro-
cyte sedimentation rate (r  .506),19 another marker of
inflammation. Notably, C4BP was also correlated with
platelet count in the patient group. This implies that there
are functional correlations between C4BP and some aspects
of platelet physiology, since activated platelets initiate com-
plement cascades27 and bind C4BP-protein S complex to
exposed phosphatidylserine.13 The significant correlation
between platelet count and levels of TCCs was expected,
since it hasbeen shownbefore thatC5b-9enhances thrombin-
induced platelet secretion.28 Furthermore, it is feasible that
elevated levels of C4BP provide increased protection of
platelets to counteract complement attack, finally leading
to increased platelet count. APC-resistant patients showed
higher levels of circulating TCCs and the multiple regres-
sion analysis revealed that it involves a direct correlation.
Since complement activates platelets and platelets can acti-
vate complement, it is difficult to determine whether hy-
percoagulation leads to more complement activation or
vice versa, but membrane assembly of C5b-9 markedly
accelerates the rate of platelet-catalyzed plasma clotting,29suggesting a direct link between C5b-9-mediated pro-
thrombinase activation and procoagulant activity accompa-
nying immunologic damage to the platelet.
In agreement with previous findings,19 we found cor-
relations between C4BP and blood lipids both in patients
and healthy controls. C4BP associates with chylomicrons,
which perhaps would otherwise cause complement activa-
tion.30 One study revealed significantly increased C4BP
levels in patients suffering from aortic atherosclerosis, and it
has been concluded that C4BP serum level can serve as an
independent indicator of aortic atherosclerosis.31 Possibly,
the determination of C4BP plasma levels in CLI patients
could also be used as a predictor of the degree of athero-
sclerosis. Moreover, C4BP might be associated with lipid
metabolism in other ways. However, one has to be careful
in judging serum lipid levels in our study, since they may be
falsely low in patients with CLI.32
In our study, both C4BPtot and C4BP levels were
significantly lower in CLI patients treated with the antico-
agulant warfarin in comparison to patients without such
treatment. A diminution in C4BP plasma concentration
was already found in patients with inherited protein S
deficiency;33 and the concentration of protein S itself is
known to likewise decrease during warfarin therapy.34 The
molecular mechanisms for the correlation between de-
creased protein S and decreased C4BP levels during warfa-
rin treatment still have to be elucidated, but our finding
implies that the level of protein S influences the synthesis of
C4BPtot and C4BP by hepatocytes.
In conclusion, CLI patients showed elevated plasma
levels of circulating TCCs and of the complement inhibitor
C4BP. Both parameters were particularly high in patients
with gangrene, most likely due to significant tissue necrosis.
Thus, levels of C4BP andC5b-9 are related to the degree of
tissue necrosis and reflect disease severity in CLI. More-
over, correlations with other biomarkers that were found
help to understand the pathophysiology of the disease and
can facilitate the research for new diagnostic tools and
clinical assays. The results of this study suggest that a
treatment of CLI patients with emerging complement in-
hibitors might be beneficial to limit inflammation and
improve the clinical outcome.
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